Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986454 in Rheumatoid Arthritis
NCT07171983Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of BMS-986454 in rheumatoid arthritis (RA) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events at 6 months, Number of participants with serious adverse events at 6 months and 4 more. Started Feb 2026; status: recruiting.
02
Drugs
BMS-986454
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07171983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07171983.